{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:01Z","timestamp":1790806501167,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>\n                      Meningiomas express the somatostatin receptor (SSTR), which normal bone and brain lack. PET imaging with SSTR ligands such as\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE have been recently shown to aid in the imaging and identification of menginiomas. We hypothesize that\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT in conjunction with MRI aids in radiation (RT) target volume delineation and evaluating treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Nineteen patients with meningiomas underwent\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT and MRI for RT planning and\/or post-treatment follow-up. Meningiomas were grade I (n\u2009=\u20099) or not biopsied (n\u2009=\u20098) and frequently involved base of skull (n\u2009=\u200910). Ten (53%) patients received post-operative RT and 9 (47%) received fractaionted RT. In the subgroup that underwent both pre- and post-RT\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET as well as MRI (n\u2009=\u200910), ROVER (ABX GmbH, Radeberg, Germany) adaptive thresholding software was utilized to measure total lesion activity (mean and max) before and after treatment. Tumor volume based on MRI was calculated before and after treatment. Total lesion activity and tumor volume changes were compared using Wilcoxon signed rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT identified intraosseous (n\u2009=\u20094, 22%), falcine (n\u2009=\u20095, 26%) and satellite lesions (n\u2009=\u20093, 19%) and clarified the diagnosis of meningioma, resulting in a change in management in three patients. Mean\u00a0total lesion activity decreased 14.7% (median), from pre to post-RT\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET [range 97\u20138.5% (25\u201375%),S\u2009=\u2009\u2212\u200926.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0039]. Max total lesion activity decreased\u00a036% (median) over the same period [range 105\u201315% (25\u201375%), S\u2009=\u2009\u2212\u200926.5\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0039]. In contrast, meningioma volumes based on MRI measurements did not significantly change per RECIST criteria and Wilcoxon signed rank test (S\u2009=\u2009\u2212\u20093,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7422).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT helped confirm suspected diagnoses and delineate target volumes particularly when lesions involved osseous structures and the falx. Mean and max total tumor\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE activity on PET\/CT decreased at three months following RT despite stable tumor volumes on MRI. Future studies are warranted to (1) assess the sensitivity and specificity of\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT, (2) evaluate the impact of\n                      <jats:sup>68<\/jats:sup>\n                      \u00a0Ga-DOTATATE PET\/CT-based planning on treatment outcomes, and (3) assess the prognostic significance of these post-treatment imaging changes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-021-01875-6","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T04:03:00Z","timestamp":1629086580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas"],"prefix":"10.1186","volume":"16","author":[{"given":"Emily S.","family":"Kowalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Khairnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton A.","family":"Gryaznov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Koroulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-1575","authenticated-orcid":false,"given":"Mark","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"suppl_4","key":"1875_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol. 2018;20(suppl_4):iv1\u201386. https:\/\/doi.org\/10.1093\/neuonc\/noy131.","journal-title":"Neuro Oncol"},{"key":"1875_CR2","first-page":"3455","volume":"54","author":"JC Reubi","year":"1994","unstructured":"Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54:3455\u20139.","journal-title":"Cancer Res"},{"key":"1875_CR3","doi-asserted-by":"publisher","DOI":"10.3171\/2016.8.JNS16995","author":"T Graillon","year":"2017","unstructured":"Graillon T, Romano D, Defilles C, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017. https:\/\/doi.org\/10.3171\/2016.8.JNS16995.","journal-title":"J Neurosurg"},{"issue":"11","key":"1875_CR4","first-page":"1913","volume":"39","author":"S Klutmann","year":"1998","unstructured":"Klutmann S, Bohuslavizki KH, Brenner W, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998;39(11):1913\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"1875_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347\u201353. https:\/\/doi.org\/10.2967\/jnumed.114.149120.","journal-title":"J Nucl Med"},{"key":"1875_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2155-3","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of68Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012. https:\/\/doi.org\/10.1007\/s00259-012-2155-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1875_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/01676830.2014.959185","volume":"34","author":"A Klingenstein","year":"2015","unstructured":"Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET\/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34(1):16\u201322. https:\/\/doi.org\/10.3109\/01676830.2014.959185.","journal-title":"Orbit"},{"issue":"10","key":"1875_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","volume":"58","author":"WG Kunz","year":"2017","unstructured":"Kunz WG, Jungblut LM, Kazmierczak PM, et al. Improved detection of transosseous meningiomas using68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58(10):1580\u20137. https:\/\/doi.org\/10.2967\/jnumed.117.191932.","journal-title":"J Nucl Med"},{"issue":"1","key":"1875_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijrobp.2012.03.021","volume":"85","author":"R Graf","year":"2013","unstructured":"Graf R, Nyuyki F, Steffen IG, et al. Contribution of 68Ga-DOTATOC PET\/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):68\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1875_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.12.006","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.12.006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1875_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-4-56","author":"B Gehler","year":"2009","unstructured":"Gehler B, Paulsen F, \u00d6ks\u00fcz MT, et al. [68Ga]-DOTATOC-PET\/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009. https:\/\/doi.org\/10.1186\/1748-717X-4-56.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00259-009-1270-2","volume":"37","author":"F Nyuyki","year":"2010","unstructured":"Nyuyki F, Plotkin M, Graf R, et al. Potential impact of 68Ga-DOTATOC PET\/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010;37(2):310\u20138. https:\/\/doi.org\/10.1007\/s00259-009-1270-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1875_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1875_CR14","first-page":"901","volume":"17","author":"O Ortiz","year":"1996","unstructured":"Ortiz O, Schochet SS, Kotzan JM, Kostick D. Radiologic-pathologic correlation meningioma of the optic nerve sheath. Am J Neuroradiol. 1996;17(5):901\u20136.","journal-title":"Am J Neuroradiol"},{"key":"1875_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04591-2","author":"K Kessell","year":"2019","unstructured":"Kessell K, Weber W, Yakushev I, Fischer H, Voglhuber T, Diehl C, Straub C, Zimmer C, Wiestler B, Gempt J, Meyer BCS. Integration of PET-imaging Into radiotherapy treatment planning for low-grade meningiomas improves outcome. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04591-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1875_CR16","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","volume":"19","author":"N Galldiks","year":"2017","unstructured":"Galldiks N, Albert NL, Sommerauer M, et al. PET imaging in patients with meningioma\u2014report of the RANO\/PET group. Neuro Oncol. 2017;19(12):1576\u201387. https:\/\/doi.org\/10.1093\/neuonc\/nox112.","journal-title":"Neuro Oncol"},{"issue":"12","key":"1875_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s002590000335","volume":"27","author":"O Gudjonsson","year":"2000","unstructured":"Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergstrom M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methioine PET. Eur J Nucl Med. 2000;27(12):1793\u20139.","journal-title":"Eur J Nucl Med"},{"key":"1875_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-005-0483-9","author":"A Nicolato","year":"2005","unstructured":"Nicolato A, Giorgetti P, Foroni R, et al. Gamma knife radiosurgery in skull base meningiomas: A possible relationship between somatostatin receptor decrease and early neurological improvement without tumour shrinkage at short-term imaging follow-up. Acta Neurochir (Wien). 2005. https:\/\/doi.org\/10.1007\/s00701-005-0483-9.","journal-title":"Acta Neurochir (Wien)"},{"key":"1875_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607427","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/nejmoa1607427.","journal-title":"N Engl J Med"},{"issue":"7","key":"1875_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/neuonc\/now001","volume":"18","author":"M Sommerauer","year":"2016","unstructured":"Sommerauer M, Burkhardt JK, Frontzek K, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18(7):1021\u20137. https:\/\/doi.org\/10.1093\/neuonc\/now001.","journal-title":"Neuro Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01875-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T04:08:30Z","timestamp":1629086910000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01875-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01875-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the IRB of the University of Maryland Baltimore. No consent was required given this was a retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mark Mishra MD has received honoraria and travel funding from Varian Medical Systems, which was not used for this project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}